Ruth L Vinall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5358404/publications.pdf

Version: 2024-02-01

687363 794594 21 434 13 19 citations h-index g-index papers 21 21 21 732 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	MiRâ€34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53â€Rb pathway status. International Journal of Cancer, 2012, 130, 2526-2538.	5.1	96
2	Nrdp1-Mediated Regulation of ErbB3 Expression by the Androgen Receptor in Androgen-Dependent but not Castrate-Resistant Prostate Cancer Cells. Cancer Research, 2010, 70, 5994-6003.	0.9	49
3	GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate, 2007, 67, 521-535.	2.3	37
4	Combination Treatment of Prostate Cancer Cell Lines with Bioactive Soy Isoflavones and Perifosine Causes Increased Growth Arrest and/or Apoptosis. Clinical Cancer Research, 2007, 13, 6204-6216.	7.0	36
5	Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. Endocrine-Related Cancer, 2012, 19, 759-777.	3.1	34
6	Dual Blockade of PKA and NF–κB Inhibits H2 Relaxin-Mediated Castrate-Resistant Growth of Prostate Cancer Sublines and Induces Apoptosis. Hormones and Cancer, 2011, 2, 224-238.	4.9	32
7	Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. American Journal of Veterinary Research, 2012, 73, 1626-1633.	0.6	23
8	Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. Genes and Cancer, 2016, 7, 86-97.	1.9	22
9	Evidence for an alternate molecular progression in prostate cancer. DMM Disease Models and Mechanisms, 2012, 5, 914-20.	2.4	20
10	Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgenâ€dependent and independent prostate cancer cell lines. BJU International, 2008, 102, 1458-1466.	2.5	18
11	Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators. International Journal of Molecular Sciences, 2019, 20, 1285.	4.1	16
12	MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples. BMC Veterinary Research, 2017, 13, 339.	1.9	15
13	Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. PLoS ONE, 2016, 11, e0146256.	2.5	13
14	COVID-19-Driven Improvements and Innovations in Pharmacy Education: A Scoping Review. Pharmacy (Basel, Switzerland), 2022, 10, 60.	1.6	8
15	Genistein Combined Polysaccharide (GCP) Can Inhibit Intracrine Androgen Synthesis in Prostate Cancer Cells. Biomedicines, 2020, 8, 282.	3.2	7
16	Use of End-of-Class Quizzes to Promote Pharmacy Student Self-Reflection, Motivate Students to Improve Study Habits, and to Improve Performance on Summative Examinations. Pharmacy (Basel,) Tj ETQq0 0	0 rgBaT/Ov	verløck 10 Tf 50
17	Use of Concept Mapping to Identify Expectations of Pharmacy Students Selecting Elective Courses. Pharmacy (Basel, Switzerland), 2021, 9, 14.	1.6	2
18	Use of Team-Based Learning Pedagogy to Prepare for a Pharmacy School Accreditation Self-Study. Pharmacy (Basel, Switzerland), 2021, 9, 148.	1.6	1

#	Article	IF	CITATIONS
19	Use of RNA-Seq and a Transgenic Mouse Model to Identify Genes Which May Contribute to Mutant p53-Driven Prostate Cancer Initiation. Biology, 2022, 11, 218.	2.8	1
20	Impact of Completion of a Pre-Pharmacy Biochemistry Course and Competency Levels in Pre-Pharmacy Courses on Pharmacy Student Performance. Pharmacy (Basel, Switzerland), 2019, 7, 117.	1.6	0
21	Androgen Receptor-Mediated Nuclear Transport of NRDP1 in Prostate Cancer Cells Is Associated with Worse Patient Outcomes. Cancers, 2021, 13, 4425.	3.7	O